Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder

Zhan Lim, Kingsley Wong, Jenny Downs, Keely Bebbington, Scott Demarest, Helen Leonard

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Variants within the CDKL5 gene result in a severe epileptic encephalopathy now known as the CDKL5 Deficiency Disorder. Phenotypic characteristics include global developmental delay and early seizure onset with poor response to anti-epileptic medications. Vagus nerve stimulation (VNS) has been used in other populations as an adjunct treatment for refractory epilepsy with seizure reduction reported in over half of patients. This study aimed to investigate the role of VNS in the CDKL5 Deficiency Disorder. Methods: The International CDKL5 Disorder Database collects information on individuals with the CDKL5 Deficiency Disorder. Families provide information regarding seizure characteristics and their pharmaceutical and non-pharmaceutical management including VNS use. Descriptive statistics and time to event analyses were performed. Clinical vignettes were also provided from patients attending the CDKL5 Center of Excellence at Children's Hospital Colorado. Results: Individuals who had a pathogenic CDKL5 variant and on whom information regarding VNS treatment was available were identified (n = 222). Previous or current use of VNS was reported for 38 (17.1%), with a median age at implantation of 4.9 years. Improvements in seizure control were reported in over two-thirds (25/36, 69%); including reduction in frequency (17/25, 68%), duration (18/25, 72%) and intensity (15/25, 60%) of seizures. Median duration of VNS use before any seizure improvement was 73 days. Behavioural changes such as improved mood and alertness were reported in nine individuals. Early termination of VNS secondary to side effects was reported in three cases. There was no reduction in number of AEDs for those with VNS treatment. Conclusion: Our study suggests that VNS is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy. Additional benefits such as mood and behavioural improvements provide further support of its use in the CDKL5 Deficiency Disorder. Future studies are required to determine the optimal settings and therapeutic potential for this treatment.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalEpilepsy Research
Volume146
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Seizures
Therapeutics
Brain Diseases
Databases

Cite this

Lim, Zhan ; Wong, Kingsley ; Downs, Jenny ; Bebbington, Keely ; Demarest, Scott ; Leonard, Helen. / Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder. In: Epilepsy Research. 2018 ; Vol. 146. pp. 36-40.
@article{fce672a39945429f85ef0fc5dfe8e178,
title = "Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder",
abstract = "Background: Variants within the CDKL5 gene result in a severe epileptic encephalopathy now known as the CDKL5 Deficiency Disorder. Phenotypic characteristics include global developmental delay and early seizure onset with poor response to anti-epileptic medications. Vagus nerve stimulation (VNS) has been used in other populations as an adjunct treatment for refractory epilepsy with seizure reduction reported in over half of patients. This study aimed to investigate the role of VNS in the CDKL5 Deficiency Disorder. Methods: The International CDKL5 Disorder Database collects information on individuals with the CDKL5 Deficiency Disorder. Families provide information regarding seizure characteristics and their pharmaceutical and non-pharmaceutical management including VNS use. Descriptive statistics and time to event analyses were performed. Clinical vignettes were also provided from patients attending the CDKL5 Center of Excellence at Children's Hospital Colorado. Results: Individuals who had a pathogenic CDKL5 variant and on whom information regarding VNS treatment was available were identified (n = 222). Previous or current use of VNS was reported for 38 (17.1{\%}), with a median age at implantation of 4.9 years. Improvements in seizure control were reported in over two-thirds (25/36, 69{\%}); including reduction in frequency (17/25, 68{\%}), duration (18/25, 72{\%}) and intensity (15/25, 60{\%}) of seizures. Median duration of VNS use before any seizure improvement was 73 days. Behavioural changes such as improved mood and alertness were reported in nine individuals. Early termination of VNS secondary to side effects was reported in three cases. There was no reduction in number of AEDs for those with VNS treatment. Conclusion: Our study suggests that VNS is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy. Additional benefits such as mood and behavioural improvements provide further support of its use in the CDKL5 Deficiency Disorder. Future studies are required to determine the optimal settings and therapeutic potential for this treatment.",
keywords = "CDKL5 Deficiency Disorder, Cyclin-dependent kinase-like 5 gene, Refractory epilepsy, Vagus nerve stimulation",
author = "Zhan Lim and Kingsley Wong and Jenny Downs and Keely Bebbington and Scott Demarest and Helen Leonard",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.eplepsyres.2018.07.013",
language = "English",
volume = "146",
pages = "36--40",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Pergamon",

}

Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder. / Lim, Zhan; Wong, Kingsley; Downs, Jenny; Bebbington, Keely; Demarest, Scott; Leonard, Helen.

In: Epilepsy Research, Vol. 146, 01.10.2018, p. 36-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder

AU - Lim, Zhan

AU - Wong, Kingsley

AU - Downs, Jenny

AU - Bebbington, Keely

AU - Demarest, Scott

AU - Leonard, Helen

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Variants within the CDKL5 gene result in a severe epileptic encephalopathy now known as the CDKL5 Deficiency Disorder. Phenotypic characteristics include global developmental delay and early seizure onset with poor response to anti-epileptic medications. Vagus nerve stimulation (VNS) has been used in other populations as an adjunct treatment for refractory epilepsy with seizure reduction reported in over half of patients. This study aimed to investigate the role of VNS in the CDKL5 Deficiency Disorder. Methods: The International CDKL5 Disorder Database collects information on individuals with the CDKL5 Deficiency Disorder. Families provide information regarding seizure characteristics and their pharmaceutical and non-pharmaceutical management including VNS use. Descriptive statistics and time to event analyses were performed. Clinical vignettes were also provided from patients attending the CDKL5 Center of Excellence at Children's Hospital Colorado. Results: Individuals who had a pathogenic CDKL5 variant and on whom information regarding VNS treatment was available were identified (n = 222). Previous or current use of VNS was reported for 38 (17.1%), with a median age at implantation of 4.9 years. Improvements in seizure control were reported in over two-thirds (25/36, 69%); including reduction in frequency (17/25, 68%), duration (18/25, 72%) and intensity (15/25, 60%) of seizures. Median duration of VNS use before any seizure improvement was 73 days. Behavioural changes such as improved mood and alertness were reported in nine individuals. Early termination of VNS secondary to side effects was reported in three cases. There was no reduction in number of AEDs for those with VNS treatment. Conclusion: Our study suggests that VNS is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy. Additional benefits such as mood and behavioural improvements provide further support of its use in the CDKL5 Deficiency Disorder. Future studies are required to determine the optimal settings and therapeutic potential for this treatment.

AB - Background: Variants within the CDKL5 gene result in a severe epileptic encephalopathy now known as the CDKL5 Deficiency Disorder. Phenotypic characteristics include global developmental delay and early seizure onset with poor response to anti-epileptic medications. Vagus nerve stimulation (VNS) has been used in other populations as an adjunct treatment for refractory epilepsy with seizure reduction reported in over half of patients. This study aimed to investigate the role of VNS in the CDKL5 Deficiency Disorder. Methods: The International CDKL5 Disorder Database collects information on individuals with the CDKL5 Deficiency Disorder. Families provide information regarding seizure characteristics and their pharmaceutical and non-pharmaceutical management including VNS use. Descriptive statistics and time to event analyses were performed. Clinical vignettes were also provided from patients attending the CDKL5 Center of Excellence at Children's Hospital Colorado. Results: Individuals who had a pathogenic CDKL5 variant and on whom information regarding VNS treatment was available were identified (n = 222). Previous or current use of VNS was reported for 38 (17.1%), with a median age at implantation of 4.9 years. Improvements in seizure control were reported in over two-thirds (25/36, 69%); including reduction in frequency (17/25, 68%), duration (18/25, 72%) and intensity (15/25, 60%) of seizures. Median duration of VNS use before any seizure improvement was 73 days. Behavioural changes such as improved mood and alertness were reported in nine individuals. Early termination of VNS secondary to side effects was reported in three cases. There was no reduction in number of AEDs for those with VNS treatment. Conclusion: Our study suggests that VNS is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy. Additional benefits such as mood and behavioural improvements provide further support of its use in the CDKL5 Deficiency Disorder. Future studies are required to determine the optimal settings and therapeutic potential for this treatment.

KW - CDKL5 Deficiency Disorder

KW - Cyclin-dependent kinase-like 5 gene

KW - Refractory epilepsy

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=85050698470&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2018.07.013

DO - 10.1016/j.eplepsyres.2018.07.013

M3 - Article

VL - 146

SP - 36

EP - 40

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

ER -